文献速递食管胃疾病与幽门螺杆菌

欧洲幽门螺杆菌根除治疗中益生菌的处方模式、有效性与安全性:欧洲幽门螺杆菌管理登记研究结果

Probiotics Prescribed With Helicobacter pylori Eradication Therapy in Europe: Usage Pattern, Effectiveness, and Safety. Results From the European Registry on Helicobacter pylori Management (Hp-EuReg).
PubMed 文献 · Am J Gastroenterol · 2025-02-04

该研究基于欧洲幽门螺杆菌管理登记研究(Hp-EuReg)的前瞻性非干预数据,纳入36,699个治疗记录,其中8,233个(22%)处方了益生菌。分析显示益生菌使用与更高的根除有效性相关(OR 1.631,95%CI 1.456-1.828),且在中欧与不良事件总体发生率(OR 0.656,95%CI 0.516-0.888)和严重不良事件(OR 0.312,95%CI 0.217-0.449)降低相关。乳杆菌属与疗效提升相关,双歧杆菌属和酵母属与更好的安全性相关。

要点

  • 在欧洲登记研究中,22%的幽门螺杆菌根除治疗同时处方了益生菌。
  • 益生菌使用与根除有效性升高相关(OR 1.631,95%CI 1.456-1.828)。
  • 在中欧,益生菌使用与不良事件和严重不良事件发生率降低相关。

核心结论

  • 在欧洲,益生菌的使用与幽门螺杆菌根除治疗更高的有效性和安全性相关。
  • 乳杆菌属与治疗有效性提升相关,而双歧杆菌属和酵母属与更好的安全性相关。

研究设计与样本

  • 国际、前瞻性、非干预性登记研究,收集欧洲胃肠病学家的临床实践数据,数据截至2021年3月在AEG-REDCap收集并质控。
  • 共记录36,699个治疗,其中8,233个(22%)处方了益生菌;有效性采用改良意向性治疗分析,按地理区域区分。

主要发现

  • 总体分析中,益生菌使用与更高的有效性相关(OR 1.631,95%CI 1.456-1.828)。
  • 在三联疗法(OR 1.702,95%CI 1.403-2.065)、四联疗法(OR 1.383,95%CI 0.996-1.920)、铋剂四联疗法(OR 1.248,95%CI 1.003-1.554)和序贯疗法(OR 3.690,95%CI 2.686-5.069)中,益生菌使用与有效性相关。
  • 在东欧,乳杆菌属与一线三联疗法(OR 2.625,95%CI 1.911-3.606)和一线铋剂四联疗法(OR 1.587,95%CI 1.117-2.254)的更高有效性相关。
  • 在中欧,益生菌使用与不良事件总体发生率降低(OR 0.656,95%CI 0.516-0.888)和严重不良事件发生率降低(OR 0.312,95%CI 0.217-0.449)相关。
  • 双歧杆菌属与总体不良事件(OR 0.725,95%CI 0.592-0.888)和严重不良事件(OR 0.254,95%CI 0.185-0.347)降低相关;在铋剂四联方案下,酵母属与总体不良事件(OR 0.54,95%CI 0.32-0.91)和严重不良事件(OR 0.257,95%CI 0.123-0.536)降低相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: To evaluate the prescription patterns, effectiveness, and safety of adding probiotics to Helicobacter pylori eradication therapy, in Europe. METHODS: International, prospective, noninterventional registry of the clinical practice of the European gastroenterologists. Data were collected and quality reviewed until March 2021 at AEG-REDCap. The effectiveness was evaluated by modified intention-to-treat analysis, differentiating by geographic areas. Adverse events (AEs) were categorized as mild, moderate, and severe. RESULTS: Overall, 36,699 treatments were recorded, where 8,233 (22%) were prescribed with probiotics. Probiotics use was associated with higher effectiveness in the overall analysis (odds ratio [OR] 1.631, 95% confidence interval [CI] 1.456-1.828), as well as in triple (OR 1.702, 95% CI 1.403-2.065), quadruple (OR 1.383, 95% CI 0.996-1.920), bismuth quadruple (OR 1.248, 95% CI 1.003-1.554), and sequential therapies (OR 3.690, 95% CI 2.686-5.069). Lactobacillus genus was associated with a higher therapy effectiveness in Eastern Europe when triple (OR 2.625, 95% CI 1.911-3.606) and bismuth quadruple (OR 1.587, 95% CI 1.117-2.254) first-line therapies were prescribed. In Central Europe, the use of probiotics was associated with a decrease in both the overall incidence of AEs (OR 0.656, 95% CI 0.516-0.888) and severe AEs (OR 0.312, 95% CI 0.217-0.449). Bifidobacterium genus was associated with lower overall (OR 0.725, 95% CI 0.592-0.888) and severe (OR 0.254, 95% CI 0.185-0.347) AEs, and Saccharomyces was associated with reduced overall (OR 0.54, 95% CI 0.32-0.91) and severe (OR 0.257, 95% CI 0.123-0.536) AEs under quadruple-bismuth regimen. DISCUSSION: In Europe, the use of probiotics was associated with higher effectiveness and safety of H. pylori eradication therapy. Lactobacillus improved treatment effectiveness, whereas Bifidobacterium and Saccharomyces were associated with a better safety profile.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Casas Deza D, Alcedo J, Lafuente M, et al. Probiotics Prescribed With Helicobacter pylori Eradication Therapy in Europe: Usage Pattern, Effectiveness, and Safety. Results From the European Registry on Helicobacter pylori Management (Hp-EuReg). Am J Gastroenterol. 2025. PMID: 39902822. doi:10.14309/ajg.0000000000003351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。